GlassScriptPhysician profile
Derek Y Yuan
NPI 1548503642
$75,397.94
in general payments reported to CMS, 2019-2025
32 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $699 · 2021: $18K · 2022: $8,951 · 2023: $6,641 · 2024: $9,997 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $2,917 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,286.05 |
| Food and Beverage | $2,916.51 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50,490.57 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $20,982.17 | 2023-2025 | |
| Allergan, INC. | $2,003.94 | 2019-2021 | |
| Amgen INC. | $377.60 | 2019-2020 | |
| Sk Life Science, INC. | $259.80 | 2022-2025 | |
| Lundbeck LLC | $171.68 | 2020-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $149.69 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Lilly USA, LLC | $117.52 | 2019-2024 | Amyvid, Emgality |
| Emd Serono, INC. | $103.71 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $73.05 | 2019-2023 | Xtampza |
| Mdd US Operations, LLC | $64.14 | 2019-2025 | |
| Genzyme Corporation | $43.28 | 2020 | |
| Amneal Pharmaceuticals LLC | $43.09 | 2020-2025 | Brekiya |
| Impel Pharmaceuticals INC. | $40.40 | 2023 | Trudhesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.63 | 2024 | Intracept |
| Assertio Therapeutics, INC. | $32.04 | 2019 | |
| Eisai INC. | $31.92 | 2024 | |
| Merz North America, INC. | $31.45 | 2020 | |
| Alexion Pharmaceuticals, INC. | $30.00 | 2020 | |
| Sentynl Therapeutics, INC. | $25.51 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.47 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.35 | 2020 | |
| Biodelivery Sciences International, INC. | $16.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.36 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.00 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.69 | 2020 | |
| Genentech USA, INC. | $14.01 | 2019 | |
| Biogen, INC. | $12.89 | 2020 | |
| Ibsa Pharma INC. | $12.72 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $12.18 | 2022 | |
| Spr Therapeutics, INC | $6.85 | 2023 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Yuan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.